Page last updated: 2024-12-04

glyceraldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glyceraldehyde: An aldotriose containing the propionaldehyde structure with hydroxy groups at the 2- and 3-positions. It is involved in the formation of ADVANCED GLYCOSYLATION END PRODUCTS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glyceraldehyde : An aldotriose comprising propanal having hydroxy groups at the 2- and 3-positions. It plays role in the formation of advanced glycation end-products (AGEs), a deleterious accompaniment to ageing. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

aldose : Aldehydic parent sugars (polyhydroxy aldehydes H[CH(OH)]nC(=O)H, n >= 2) and their intramolecular hemiacetals. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID751
CHEMBL ID173813
CHEBI ID5445
CHEBI ID15693
MeSH IDM0009407

Synonyms (90)

Synonym
propanal, 2,3-dihydroxy-
SGCUT00090
u 1188
propanal,3-dihydroxy-
nsc-67934
.alpha.,.beta.-dihydroxypropionaldehyde
NSC67934 ,
glycerinaldehyde
dl-glyc
glyceric aldehyde
glycerinformal
wln: vhyq1q
propionaldehyde,3-dihydroxy-
brn 0635844
einecs 200-290-0
ai3-24475
propionaldehyde, 2,3-dihydroxy-
einecs 206-695-9
nsc 67934
glyceraldehyde, (+-)-
(+-)-glyceraldehyde
glyzerinaldehyd
dl-glyceraldehyde
gliceraldehido
glyceraldehyd
glycerinaldehyd
CHEBI:5445 ,
56-82-6
DLG ,
CHEBI:15693
an aldose
2,3-dihydroxypropionaldehyde
glycerose
367-47-5
2,3-dihydroxypropanal ,
glyceraldehyde
aldose
alpha,beta-dihydroxypropionaldehyde
C02154
aldotriose
TO_000052
dl-glyceraldehyde, >=90% (gc)
G-4100
dl-glyceraldehyde (dimer), 93.0%+
G-4140
0559E623-301F-4EC2-BF9D-01F20A1706FF
BMSE000225
2,3-dihydroxy-propionaldehyde
CHEMBL173813
3-01-00-03282 (beilstein handbook reference)
di19xsg16h ,
unii-di19xsg16h
A827816
FT-0624360
FT-0627589
FT-0625464
AKOS015903493
glyceraldehyde [mi]
glyceraldehyde, (+/-)-
glyceraldehyde, dl-
(+/-)-glyceraldehyde
478529-62-3
d,l-glyceraldehyde
d-(+)-glyceraldehyde; (r)-2,3-dihydroxy-propanal
bdbm16241
dl-glyceric aldehyde
propanal, 2,3-dihydroxy-, (.+/-.)-
glyceraldehyde, (.+/-.)-
2,3-dihydroxypropanal #
dl-[1-13c]glyceraldehyde
dl-[2-13c]glyceraldehyde
mfcd00064379
STL453543
delta-2,3-dihydroxypropanal
delta-glyceraldehyde
dihydroxypropionaldehyde
delta-(+)-glyceraldehyde
delta-2,3-dihydroxypropionaldehyde
delta-glycerose
delta-aldotriose
(+/-)-2,3-dihydroxy-propanal
DTXSID90861586
Q423211
E75815
dl-[1,2,3,3'-2h4]glyceraldehyde
d-[1,2,3-13c3]glyceraldehyde
SB44379
SY076248
CS-0102543
HY-128748

Research Excerpts

Overview

L-Glyceraldehyde is a competitive inhibitor of sn-glycerol 3-phosphate. It acts as a source of energy and monomers in a new model of the origin of life.

ExcerptReferenceRelevance
"Glyceraldehyde is a safe and effective cross-linking agent that could significantly enhance the sclera biomechanical strength. "( [Experimental study of glyceraldehyde cross-linking of posterior scleral on FDM in guinea pigs].
Chu, Y; Han, F; Han, Q; Wang, Y; Zhao, K, 2014
)
2.16
"l-Glyceraldehyde 3-phosphate is a competitive inhibitor of sn-glycerol 3-phosphate in the reactions catalyzed by acyl coenzyme A:sn-glycerol 3-phosphate acyltransferase (K(i) of 1.8 mM) and cytidine 5'-diphosphate-diglyceride:sn-glycerol 3-phosphate phosphatidyltransferase (K(i) of 2.7 mM)."( L-Glyceraldehude 3-phosphate, a bactericidal agent.
Engel, R; Tang, CT; Tropp, BE, 1977
)
0.82
"Glyceraldehyde acts as a source of energy and monomers in a new model of the origin of life. "( The triose model: glyceraldehyde as a source of energy and monomers for prebiotic condensation reactions.
Weber, AL, 1987
)
2.05

Effects

Glyceraldehyde (GA) has been used to study insulin secretion for decades. It is widely assumed that beta-cell metabolism of GA after its phosphorylation by triokinase is similar to metabolism of glucose; that is metabolism through distal glycolysis and oxidation in mitochondria.

ExcerptReferenceRelevance
"Glyceraldehyde (GA) has been used to study insulin secretion for decades and it is widely assumed that beta-cell metabolism of GA after its phosphorylation by triokinase is similar to metabolism of glucose; that is metabolism through distal glycolysis and oxidation in mitochondria. "( Stimulation of insulin release by glyceraldehyde may not be similar to glucose.
Chaplen, FW; Drought, H; Gong, Q; MacDonald, MJ; Triplett, CK, 2006
)
2.06
"Glyceraldehyde, which has antiglycolytic activity, was assessed for potential in preserving glucose in blood specimens."( Glyceraldehyde preserves glucose concentrations in whole blood specimens.
Landt, M, 2000
)
2.47
"Glyceraldehyde has been known to be an insulin secretagogue for more than 15 years. "( Does glyceraldehyde enter pancreatic islet metabolism via both the triokinase and the glyceraldehyde phosphate dehydrogenase reactions? A study of these enzymes in islets.
MacDonald, MJ, 1989
)
2.23
"Glyceraldehyde has been demonstrated to be an antisickling agent in vitro. "( Enhanced survival of sickle erythrocytes upon treatment with glyceraldehyde.
Benjamin, LJ; Manning, JM, 1986
)
1.96

Actions

Glyceraldehyde did not cause translocation of islet PKC under conditions in which PMA stimulated redistribution of enzyme activity. Only five of a total 24 amino groups per alpha beta dimer of hemoglobin S are reactive.

ExcerptReferenceRelevance
"Glyceraldehyde also displays selectivity; only five of a total 24 amino groups per alpha beta dimer of hemoglobin S are reactive."( The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde.
Acharya, AS; Manning, JM, 1984
)
1.22
"Glyceraldehyde did not cause translocation of islet PKC under conditions in which PMA stimulated redistribution of enzyme activity."( Activation of protein kinase C is not required for glyceraldehyde-stimulated insulin secretion from rat islets.
Howell, SL; Jones, PM; Persaud, SJ, 1991
)
1.25
"D-Glyceraldehyde caused an increase in the glycerol 3-phosphate content and a decrease in the dihydroxyacetone phosphate content, whereas dihydroxyacetone increased the content of both metabolites."( Metabolic effects of D-glyceraldehyde in isolated hepatocytes.
Daneshmand, F; Davies, DR; Maswoswe, SM, 1986
)
1.14

Treatment

Glyceraldehyde treatment prevented expansion of the cornea and sclera. Treatment resulted in a significant increase in thermal stability, proteolytic resistance and improvement of biomechanical characteristics.

ExcerptReferenceRelevance
"Glyceraldehyde treatment prevented expansion of the cornea and sclera."( An in vitro intact globe expansion method for evaluation of cross-linking treatments.
Coassin, M; Huynh, J; Kornfield, JA; Mattson, MS; Schwartz, DM; Wiseman, M, 2010
)
1.08
"The glyceraldehyde treatment was resulted in a significant increase in thermal stability, proteolytic resistance and improvement of biomechanical characteristics (Young's modulus, ultimate tensile stress)."( Stabilization of scleral collagen by glycerol aldehyde cross-linking.
Danilov, NA; Grokhovskaya, TE; Ignatieva, NY; Iomdina, EN; Lunin, VV; Rudenskaya, GN; Semenova, SA, 2008
)
0.83

Toxicity

ExcerptReferenceRelevance
" The molecular mechanisms responsible for the glucose toxic effect on beta cell function involves disappearance of two important regulators of insulin promoter activity, PDX-1 and MafA."( Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes.
Harmon, JS; Robertson, R; Zhang, T; Zhou, H, 2007
)
0.34
" Reuterin was much less toxic than acrolein and only four times more toxic than diacetyl, a generally recognized as safe flavoring compound."( In vitro toxicity of reuterin, a potential food biopreservative.
Arqués, JL; Díaz-Navarro, C; Fernández-Cruz, ML; Gaya, P; Martín-Cabrejas, I; Medina, M; Navas, JM; Pérez-Del Palacio, J, 2016
)
0.43
" The toxic effects of GLAP and GA-pyridine were suppressed in the presence of anti-RAGE antibody or the soluble form of RAGE protein."( Receptor for advanced glycation end products (RAGE)-mediated cytotoxicity of 3-hydroxypyridinium derivatives.
Daikoh, T; Fujino, T; Hasegawa, T; Hayase, F; Kurachi, R; Miura, A; Murakami, Y; Usui, T; Watanabe, H, 2018
)
0.48

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters and enzyme kinetic data both in normal and in tumor-bearing animals will be presented."( Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect.
Bartosek, I; Colombo, T; Donelli, MG; Guaitani, A; Martini, A; Modica, R; Pacciarini, MA, 1976
)
0.26

Compound-Compound Interactions

ExcerptReferenceRelevance
"Antimicrobial activity of reuterin individually or in combination with nisin against different food-borne Gram-positive and Gram-negative pathogens in milk was investigated."( Antimicrobial activity of reuterin in combination with nisin against food-borne pathogens.
Arqués, JL; Fernández, J; Gaya, P; Medina, M; Nuñez, M; Rodríguez, E, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
", shifted the glucose dose-response curve to the left both for [(3)H]cyclic AMP accumulation and insulin release."( Interacting effects of sulfonylureas and glucose on cyclic AMP metabolism and insulin release in pancreatic islets of the rat.
Cerasi, E; Grill, V, 1978
)
0.26
" The dose-response curve for neonatal islets was steeper than for adult islets and the maximal response was clearly shifted towards lower glucose concentrations."( Effects of glucose on insulin release and 86Rb permeability in cultured neonatal and adult rat islets.
Atwater, I; Boschero, AC; Tombaccini, D, 1988
)
0.27
" We report a dosage dependent stimulation of both mRNA levels and insulin secretion by extracellular glucose, and present evidence that islet responsiveness can be divided into two temporal phases: an early response, apparently under post-transcriptional control, and a late phase in which insulin messenger accumulates."( Regulation and specificity of glucose-stimulated insulin gene expression in human islets of Langerhans.
Ashcroft, SJ; Gray, DW; Hammonds, P; Schofield, PN; Sutton, R, 1987
)
0.27
" Many studies of the diabetic mouse have used lean littermates (+/?) as controls despite evidence suggesting a gene dosage effect in heterozygous animals."( The dynamic insulin secretory response of isolated pancreatic islets of the diabetic mouse. Evidence for a gene dosage effect on insulin secretion.
Eddlestone, G; Klenck, RE; Lipson, LG; Molina, JM; Oldham, SB; Premdas, FH, 1984
)
0.27
" To establish a dose-response relationship, we used inflation testing to simulate the effects of increasing intraocular pressure in freshly harvested rat eyes stiffened with multiple concentrations of each agent."( Quantification of the efficacy of collagen cross-linking agents to induce stiffening of rat sclera.
Campbell, IC; Ethier, CR; Hannon, BG; Read, AT; Schwaner, SA; Sherwood, JM, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fundamental metaboliteAny metabolite produced by all living cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aldotriose
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (14)

PathwayProteinsCompounds
Glycerolipid Metabolism1124
Fructose and Mannose Degradation1830
Glycerol Kinase Deficiency1124
D-Glyceric Acidura1124
Familial Lipoprotein Lipase Deficiency1124
Fructosuria1830
Fructose Intolerance, Hereditary1830
cytidine-5'-diphosphate-glycerol biosynthesis315
N-acetylneuraminate and N-acetylmannosamine degradation I416
superpathway of N-acetylglucosamine, N-acetylmannosamine and N-acetylneuraminate degradation924
superpathway of N-acetylneuraminate degradation3979
Hexoses metabolism in proximal tubules016
Biochemical pathways: part I0466
Polyol pathway08

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)0.01000.00101.191310.0000AID318836
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
cellular detoxification of aldehydeAldo-keto reductase family 1 member B10Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B10Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionAldo-keto reductase family 1 member B10Homo sapiens (human)
lysosomeAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
mitochondrionAldo-keto reductase family 1 member B10Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID318823Activity of human AKR1B1 by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318836Inhibition of glyceraldehyde reduction activity of human AKR1B12007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318831Activity of human AKR1B10 K125L/V301L mutant by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318824Ratio of Kcat to Km for human AKR1B12007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318825Activity of human wild type AKR1B10 by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318827Activity of human AKR1B10 K125L mutant by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318832Ratio of Kcat to Km for human AKR1B10 K125L/V301L mutant2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318829Activity of human AKR1B10 V301L mutant by BSA/HPLC method2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318828Ratio of Kcat to Km for human AKR1B10 K125L mutant2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318830Ratio of Kcat to Km for human AKR1B10 V301L mutant2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID318826Ratio of Kcat to Km for human wild type AKR1B102007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,119)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990655 (58.53)18.7374
1990's117 (10.46)18.2507
2000's161 (14.39)29.6817
2010's149 (13.32)24.3611
2020's37 (3.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 80.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index80.84 (24.57)
Research Supply Index7.06 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index144.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (80.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.09%)5.53%
Reviews20 (1.72%)6.00%
Case Studies2 (0.17%)4.05%
Observational0 (0.00%)0.25%
Other1,138 (98.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]